These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

828 related items for PubMed ID: 17912154

  • 21. Inhibition of 11β-hydroxysteroid dehydrogenase 1 by carbenoxolone affects glucose homeostasis and obesity in db/db mice.
    Dhanesha N, Joharapurkar A, Shah G, Kshirsagar S, Dhote V, Sharma A, Jain M.
    Clin Exp Pharmacol Physiol; 2012 Jan; 39(1):69-77. PubMed ID: 22060140
    [Abstract] [Full Text] [Related]

  • 22. Mechanisms of disease: Selective inhibition of 11beta-hydroxysteroid dehydrogenase type 1 as a novel treatment for the metabolic syndrome.
    Tomlinson JW, Stewart PM.
    Nat Clin Pract Endocrinol Metab; 2005 Dec; 1(2):92-9. PubMed ID: 16929377
    [Abstract] [Full Text] [Related]

  • 23. Upregulation of adipose 11-beta-hydroxysteroid dehydrogenase type 1 expression in ovariectomized rats is due to obesity rather than lack of estrogen.
    Paulsen SK, Nielsen MP, Richelsen B, Bruun JM, Flyvbjerg A, Pedersen SB.
    Obesity (Silver Spring); 2008 Apr; 16(4):731-5. PubMed ID: 18379559
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Inhibition of 11beta-HSD1 as a novel treatment for the metabolic syndrome: do glucocorticoids play a role?
    Thieringer R, Hermanowski-Vosatka A.
    Expert Rev Cardiovasc Ther; 2005 Sep; 3(5):911-24. PubMed ID: 16181035
    [Abstract] [Full Text] [Related]

  • 26. Diet and the role of 11beta-hydroxysteroid dehydrogenase-1 on obesity.
    London E, Castonguay TW.
    J Nutr Biochem; 2009 Jul; 20(7):485-93. PubMed ID: 19443197
    [Abstract] [Full Text] [Related]

  • 27. 11beta-hydroxysteroid dehydrogenase type 1 inhibitors: a review of recent patents.
    Boyle CD, Kowalski TJ.
    Expert Opin Ther Pat; 2009 Jun; 19(6):801-25. PubMed ID: 19456274
    [Abstract] [Full Text] [Related]

  • 28. 11beta-Hydroxysteroid dehydrogenase type 1 inhibitors: novel agents for the treatment of metabolic syndrome and obesity-related disorders?
    Anagnostis P, Katsiki N, Adamidou F, Athyros VG, Karagiannis A, Kita M, Mikhailidis DP.
    Metabolism; 2013 Jan; 62(1):21-33. PubMed ID: 22652056
    [Abstract] [Full Text] [Related]

  • 29. Tissue-specific glucocorticoid reactivating enzyme, 11 beta-hydroxysteroid dehydrogenase type 1 (11 beta-HSD1)--a promising drug target for the treatment of metabolic syndrome.
    Masuzaki H, Flier JS.
    Curr Drug Targets Immune Endocr Metabol Disord; 2003 Dec; 3(4):255-62. PubMed ID: 14683456
    [Abstract] [Full Text] [Related]

  • 30. Dehydroepiandrosterone inhibits the amplification of glucocorticoid action in adipose tissue.
    Apostolova G, Schweizer RA, Balazs Z, Kostadinova RM, Odermatt A.
    Am J Physiol Endocrinol Metab; 2005 May; 288(5):E957-64. PubMed ID: 15613680
    [Abstract] [Full Text] [Related]

  • 31. Time of the day for 11beta-HSD1 inhibition plays a role in improving glucose homeostasis in DIO mice.
    Véniant MM, Hale C, Komorowski R, Chen MM, St Jean DJ, Fotsch C, Wang M.
    Diabetes Obes Metab; 2009 Feb; 11(2):109-17. PubMed ID: 18479468
    [Abstract] [Full Text] [Related]

  • 32. Diabetic pregnancy in rats leads to impaired glucose metabolism in offspring involving tissue-specific dysregulation of 11beta-hydroxysteroid dehydrogenase type 1 expression.
    Fujisawa Y, Nakagawa Y, Li RS, Liu YJ, Ohzeki T.
    Life Sci; 2007 Aug 09; 81(9):724-31. PubMed ID: 17692875
    [Abstract] [Full Text] [Related]

  • 33. A transgenic model of visceral obesity and the metabolic syndrome.
    Masuzaki H, Paterson J, Shinyama H, Morton NM, Mullins JJ, Seckl JR, Flier JS.
    Science; 2001 Dec 07; 294(5549):2166-70. PubMed ID: 11739957
    [Abstract] [Full Text] [Related]

  • 34. Regulation of 11beta-HSD genes in human adipose tissue: influence of central obesity and weight loss.
    Engeli S, Böhnke J, Feldpausch M, Gorzelniak K, Heintze U, Janke J, Luft FC, Sharma AM.
    Obes Res; 2004 Jan 07; 12(1):9-17. PubMed ID: 14742837
    [Abstract] [Full Text] [Related]

  • 35. Extra-adrenal regeneration of glucocorticoids by 11beta-hydroxysteroid dehydrogenase type 1: physiological regulator and pharmacological target for energy partitioning.
    Walker BR.
    Proc Nutr Soc; 2007 Feb 07; 66(1):1-8. PubMed ID: 17343766
    [Abstract] [Full Text] [Related]

  • 36. 11Beta-HSD type 1 expression in human adipose tissue: impact of gender, obesity, and fat localization.
    Paulsen SK, Pedersen SB, Fisker S, Richelsen B.
    Obesity (Silver Spring); 2007 Aug 07; 15(8):1954-60. PubMed ID: 17712112
    [Abstract] [Full Text] [Related]

  • 37. Inhibitors of 11beta-hydroxysteroid dehydrogenase type 1 for the treatment of metabolic syndrome.
    Wang M.
    Curr Opin Investig Drugs; 2006 Apr 07; 7(4):319-23. PubMed ID: 16625818
    [Abstract] [Full Text] [Related]

  • 38. 11beta-HSD1 inhibition ameliorates metabolic syndrome and prevents progression of atherosclerosis in mice.
    Hermanowski-Vosatka A, Balkovec JM, Cheng K, Chen HY, Hernandez M, Koo GC, Le Grand CB, Li Z, Metzger JM, Mundt SS, Noonan H, Nunes CN, Olson SH, Pikounis B, Ren N, Robertson N, Schaeffer JM, Shah K, Springer MS, Strack AM, Strowski M, Wu K, Wu T, Xiao J, Zhang BB, Wright SD, Thieringer R.
    J Exp Med; 2005 Aug 15; 202(4):517-27. PubMed ID: 16103409
    [Abstract] [Full Text] [Related]

  • 39. Enhanced 11beta-hydroxysteroid dehydrogenase activity, the metabolic syndrome, and systemic hypertension.
    Sukhija R, Kakar P, Mehta V, Mehta JL.
    Am J Cardiol; 2006 Aug 15; 98(4):544-8. PubMed ID: 16893715
    [Abstract] [Full Text] [Related]

  • 40. Glucocorticoids and 11beta-hydroxysteroid dehydrogenase in adipose tissue.
    Seckl JR, Morton NM, Chapman KE, Walker BR.
    Recent Prog Horm Res; 2004 Aug 15; 59():359-93. PubMed ID: 14749510
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 42.